Class information for:
Level 1: CANCER PROCOAGULANT//TISSUE FACTOR//CANCER ASSOCIATED THROMBOSIS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1606 2490 40.6 79%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
200 20446 PULMONARY EMBOLISM//VENOUS THROMBOEMBOLISM//DEEP VEIN THROMBOSIS

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CANCER PROCOAGULANT Author keyword 50 86% 1% 25
2 TISSUE FACTOR Author keyword 35 13% 11% 265
3 CANCER ASSOCIATED THROMBOSIS Author keyword 26 87% 1% 13
4 TROUSSEAUS SYNDROME Author keyword 12 50% 1% 17
5 TROUSSEAU SYNDROME Author keyword 8 52% 0% 11
6 CARCINOMA SMALL CELL MORTALITY Author keyword 8 100% 0% 5
7 CLIN HAEMATOL HAEMOSTASEOL Address 7 34% 1% 17
8 ANTICOAGULANTS ADMINISTRATION DOSAGE ADVERSE EFFECTS Author keyword 5 63% 0% 5
9 CLIN HEMATOL HEMOSTASEOL Address 4 42% 0% 8
10 HEPARIN LOW MOLECULAR WEIGHT ADMINISTRATION DOSAGE Author keyword 4 75% 0% 3

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CANCER PROCOAGULANT 50 86% 1% 25 Search CANCER+PROCOAGULANT Search CANCER+PROCOAGULANT
2 TISSUE FACTOR 35 13% 11% 265 Search TISSUE+FACTOR Search TISSUE+FACTOR
3 CANCER ASSOCIATED THROMBOSIS 26 87% 1% 13 Search CANCER+ASSOCIATED+THROMBOSIS Search CANCER+ASSOCIATED+THROMBOSIS
4 TROUSSEAUS SYNDROME 12 50% 1% 17 Search TROUSSEAUS+SYNDROME Search TROUSSEAUS+SYNDROME
5 TROUSSEAU SYNDROME 8 52% 0% 11 Search TROUSSEAU+SYNDROME Search TROUSSEAU+SYNDROME
6 CARCINOMA SMALL CELL MORTALITY 8 100% 0% 5 Search CARCINOMA++SMALL+CELL+MORTALITY Search CARCINOMA++SMALL+CELL+MORTALITY
7 ANTICOAGULANTS ADMINISTRATION DOSAGE ADVERSE EFFECTS 5 63% 0% 5 Search ANTICOAGULANTS+ADMINISTRATION++DOSAGE+ADVERSE+EFFECTS Search ANTICOAGULANTS+ADMINISTRATION++DOSAGE+ADVERSE+EFFECTS
8 HEPARIN LOW MOLECULAR WEIGHT ADMINISTRATION DOSAGE 4 75% 0% 3 Search HEPARIN++LOW+MOLECULAR+WEIGHT+ADMINISTRATION++DOSAGE Search HEPARIN++LOW+MOLECULAR+WEIGHT+ADMINISTRATION++DOSAGE
9 MELANOMA CELL ADHESION 4 75% 0% 3 Search MELANOMA+CELL+ADHESION Search MELANOMA+CELL+ADHESION
10 PLASMA D DIMER 4 50% 0% 6 Search PLASMA+D+DIMER Search PLASMA+D+DIMER

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 OCCULT CANCER 123 77% 3% 85
2 ADVANCED MALIGNANCY 115 60% 5% 125
3 MALIGNANT TISSUE 65 85% 1% 34
4 TROUSSEAUS SYNDROME 51 58% 2% 59
5 VIENNA CANCER 42 73% 1% 32
6 THROMBOPHILIC STATE 33 75% 1% 24
7 FACTOR CYTOPLASMIC DOMAIN 33 53% 2% 44
8 IV BREAST CANCER 31 73% 1% 24
9 UNSUSPECTED PULMONARY EMBOLI 23 100% 0% 10
10 ILL MEDICAL PATIENTS 20 28% 3% 63

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
The relationship between tissue factor and cancer progression: insights from bench and bedside 2012 55 92 82%
American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer 2007 438 115 40%
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer 2013 91 101 31%
Epidemiology of cancer-associated venous thrombosis 2013 36 83 69%
Low-molecular-weight heparins and cancer: Focus on antitumoral effect 2015 1 56 88%
Venous thromboembolism and prognosis in cancer 2010 49 23 78%
Role of Tissue Factor in Cancer 2009 117 58 57%
Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants 2014 5 34 68%
Systematic review: The trousseau syndrome revisited: Should we screen extensively for cancer in patients with venous thromboembolism? 2008 68 41 90%
Assessing Risk of Venous Thromboembolism in the Patient With Cancer 2009 108 94 56%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CLIN HAEMATOL HAEMOSTASEOL 7 34% 0.7% 17
2 CLIN HEMATOL HEMOSTASEOL 4 42% 0.3% 8
3 IMMUNOHEMATOL TRANSFUS MED 4 22% 0.6% 16
4 HENDERSON 4 18% 0.8% 19
5 INTERNAL VASC MED STROKE UNIT 3 100% 0.1% 3
6 HERZ KREISLAUFMED 3 50% 0.2% 4
7 ER2UPMC 2 44% 0.2% 4
8 BIOCHEM IBSIB 2 67% 0.1% 2
9 GERIATR GERONTOL METAB DIS 2 67% 0.1% 2
10 QUEENS ONCOL HEMATOL 2 67% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000197419 THROMBOCYTOSIS//TCIPA//TUMOR CELL INDUCED PLATELET AGGREGATION
2 0.0000113758 TISSUE FACTOR//TISSUE FACTOR PATHWAY INHIBITOR//TFPI
3 0.0000113141 NONBACTERIAL THROMBOTIC ENDOCARDITIS//MARANTIC ENDOCARDITIS//NON BACTERIAL THROMBOTIC ENDOCARDITIS
4 0.0000097207 RESIDUAL THROMBOSIS//RECURRENT VENOUS THROMBOEMBOLISM//ANTICOAGULANT RELATED BLEEDING
5 0.0000090693 VASCULAR TOXICITY//INTERNAL MED PERIOPERAT ASSESSMENT//BOLUS 5 FLUOROURACIL
6 0.0000080731 THROMBOPROPHYLAXIS//VENOUS THROMBOEMBOLISM//DEEP VEIN THROMBOSIS
7 0.0000066930 VENOUS THROMBOEMBOLISM PROPHYLAXIS//BLUNT SOLID ORGAN INJURY//SEQUENTIAL COMPRESSION DEVICES
8 0.0000059920 CARCINOCYTHEMIA//BONE MARROW CARCINOSIS//TUMOR BIOL METASTASIS BRANCH
9 0.0000055604 CHRONIC DISSEMINATED INTRAVASCULAR COAGULATION//ANTICOAGULANTS ADMINISTRATION AND DOSAGE//FEASIBLE STUDY
10 0.0000055109 MICROPARTICLES//ENDOTHELIAL MICROPARTICLES//PLATELET DERIVED MICROPARTICLES